1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,345 | 2,450 | 13.11. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.11. | XSpray Pharma AB: Interim Report Third Quarter 2025 | 83 | GlobeNewswire (Europe) | July-September 2025, GroupNet sales amounted to SEK 0 thousand (0)Earnings before tax amounted to SEK -47,332 thousand (-82,272)Earnings per share before dilution amounted to SEK -1.25 (-2.44)Cash flow... ► Artikel lesen | |
| XSPRAY PHARMA Aktie jetzt für 0€ handeln | |||||
| 08.10. | XSpray Pharma AB: Xspray Pharma provides update on the FDA process for Dasynoc - observations at contract manufacturer delay approval | 168 | GlobeNewswire (Europe) | • FDA has issued a Complete Response Letter (CRL) regarding Xspray Pharma's New Drug Application (NDA) for Dasynoc, referring to GMP (Good Manufacturing Practice) observations at a contract manufacturer.... ► Artikel lesen | |
| 11.09. | XSpray Pharma AB: Xspray's rights issue oversubscribed - over-allotment issue increased and fully utilized | 196 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, RUSSIA... ► Artikel lesen | |
| 26.08. | Listing of subscription rights and paid subscription shares of XSpray Pharma AB | 302 | GlobeNewswire | With effect from August 27, 2025, the subscription rights of XSpray Pharma AB will be traded on the list for Equity rights. Trading will continue up until and including September 04, 2025.
Instrument:
Subscription... ► Artikel lesen | |
| 25.08. | XSpray Pharma AB: Xspray publishes disclosure document regarding rights issue | 295 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, RUSSIA... ► Artikel lesen | |
| 21.08. | XFRA CAPITAL ADJUSTMENT INFORMATION - 21.08.2025 | 378 | Xetra Newsboard | Das Instrument 6O1 CA13810W1023 CANTER RESOURCES CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 21.08.2025 und ex Kapitalmassnahme am 22.08.2025 The instrument 6O1 CA13810W1023 CANTER RESOURCES... ► Artikel lesen | |
| 19.08. | XSpray Pharma AB: Xspray Pharma Submits XS003 to the FDA - The Company's Second Product Candidate from the HyNap Platform | 405 | GlobeNewswire (Europe) | Xspray Pharma (Nasdaq Stockholm: XSPRAY) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate XS003 (nilotinib) for the treatment of chronic... ► Artikel lesen | |
| 15.08. | XSpray Pharma AB: Interim Report Second Quarter 2025 | 177 | GlobeNewswire (Europe) | April-June 2025, GroupNet sales amounted to SEK 0 thousand (0)Earnings before tax amounted to SEK -44,885 thousand (-53,620)Earnings per share before dilution amounted to SEK -2.35 (-1.64)Cash flow... ► Artikel lesen | |
| 12.08. | Xspray Pharma Signs License Agreement With Handa Therapeutics For Dasatinib Product | 1 | RTTNews | ||
| 12.08. | XSpray Pharma AB: Xspray Pharma signs license agreement with Handa Therapeutics - to receive up to double-digit royalty on Handa's net proceeds | 208 | GlobeNewswire (Europe) | Xspray Pharma ("Xspray") has entered into a license agreement with Handa Therapeutics ("Handa") granting Handa a non-exclusive license to certain Xspray patents. The license covers commercialization... ► Artikel lesen | |
| 11.07. | XSpray Pharma AB: XSpray Pharma achieves significant milestone - demonstrating bioequivalence with absorption advantages compared to Tasigna | 167 | GlobeNewswire (Europe) | Xspray Pharma has now completed the population pharmacokinetic (PopPK) modeling that constitutes key regulatory documentation ahead of submitting a New Drug Application (NDA) for the product candidate... ► Artikel lesen | |
| 27.06. | XSpray Pharma AB: Xspray Pharma Passes FDA Pre-Approval Inspection - Key Regulatory Milestone Achieved for Dasynoc | 468 | GlobeNewswire (Europe) | Xspray Pharma AB (publ) today announces that the U.S. Food and Drug Administration (FDA) has conducted a successful Pre-Approval Inspection (PAI) of the company's manufacturing lines, located at a contract... ► Artikel lesen | |
| 14.05. | XSpray Pharma AB: FDA sets PDUFA-date for Xspray Pharma's re-submitted application for Dasynoc | 345 | GlobeNewswire (Europe) | The U.S. Food and Drug Administration (FDA) has acknowledged receipt of Xspray Pharma's re-submitted NDA (New Drug Application) for Dasynoc®. The re-submission is based on a CRL (Complete Response Letter)... ► Artikel lesen | |
| 13.05. | XSpray Pharma AB: Bulletin from the annual general meeting of Xspray Pharma AB (publ) | 132 | GlobeNewswire (Europe) | The following resolutions were passed at the annual general meeting (the "AGM") of Xspray Pharma AB (publ) ("Xspray") on 13 May 2025.
Adoption of income statement and balance sheet for the financial... ► Artikel lesen | |
| 07.05. | XSpray Pharma AB: Interim Report First Quarter 2025 | 196 | GlobeNewswire (Europe) | January - March 2025, Group• Net sales amounted to SEK 0 thousand (0)• Earnings before tax amounted to SEK -42,321 thousand (-67,781)• Earnings per share before dilution amounted to SEK -1.14 (-2.17)•... ► Artikel lesen | |
| 08.04. | XSpray Pharma AB: Xspray Pharma re-submits its FDA application | 307 | GlobeNewswire (Europe) | Xspray Pharma AB (publ) has re-submitted its application for market approval for Dasynoc®, the company's lead product candidate, an amorphous dasatinib for the treatment of leukemia. The application... ► Artikel lesen | |
| 12.02. | XSpray Pharma AB: Interim Report Fourth Quarter 2024 | 144 | GlobeNewswire (Europe) | October-December 2024, GroupNet sales amounted to SEK 0 thousand (0)Loss before tax amounted to SEK -82,002 thousand (-54,513)Earnings per share before dilution amounted to SEK -2.36 (-1.85)Cash flow... ► Artikel lesen | |
| 20.01. | XSpray Pharma AB: Xspray Pharma reports strong interim data for product candidate XS003 - confirms plan to apply for market approval in H1 2025 | 170 | GlobeNewswire (Europe) | Xspray Pharma AB (publ) today presents interim data from a food interaction study with the nilotinib product candidate (XS003). The results confirm the benefits of the company's patented HyNap technology... ► Artikel lesen | |
| 14.11.24 | Nasdaq Stockholm AB: Listing of subscription rights and paid subscription shares of Xspray Pharma AB | 392 | GlobeNewswire | With effect from November 15, 2024, the subscription rights of Xspray Pharma
AB will be traded on the list for Equity rights. Trading will continue up until
and including November 26, 2024.
Instrument:... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STRUCTURE THERAPEUTICS | 35,000 | -2,70 % | Structure Therapeutics Inc.: Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights | Topline 36-week data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for readouts by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671)... ► Artikel lesen | |
| QIAGEN | 38,695 | +0,85 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen anlässlich der jüngst präsentierten Quartalszahlen von 50 auf 46 Euro gesenkt, die Einstufung aber auf "Buy" belassen.... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,660 | -0,96 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| BIONTECH | 89,45 | -7,21 % | Sinkende Impfstoffnachfrage, Forschungs-Flops: BioNTech-Rivalen geht das Geld aus | Der Impfstoff-Pionier Moderna, der einst mit BioNTech um das wirksamste Covid-Vakzin wetteiferte, kämpft mit sinkenden Einnahmen und enttäuschenden Studienergebnissen. Noch lebt er von seinem Geldpolster... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 22,860 | -2,39 % | Arcutis completes enrollment in infant atopic dermatitis study | ||
| AVIDITY BIOSCIENCES | 70,81 | -0,01 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,260 | 0,00 % | Summit Therapeutics Inc. - 8-K, Current Report | ||
| COGENT BIOSCIENCES | 33,810 | 0,00 % | Aktien New York: Gewinne dank Signalen für Shutdown-Ende | NEW YORK (dpa-AFX) - An den US-Börsen knüpfen die Kurse am Montag mit einer Erholung an die späte Kursstabilisierung vom Freitag an. Wie schon zuvor in Asien und Europa hellten Anzeichen für eine mögliche... ► Artikel lesen | |
| EVOTEC | 5,452 | +1,34 % | Evotec: Schlimme Achterbahnfahrt - Kontron, Limes, Nordex, SBF und TeamViewer im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 44,290 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | - Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 - - Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 - - Conference call... ► Artikel lesen | |
| ANNEXON | 2,680 | 0,00 % | Annexon prices public offering of shares at $2.60 each | ||
| ARS PHARMACEUTICALS | 8,410 | -5,98 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy (epinephrine nasal spray) | $32.5 million in revenue, including $31.3 million in neffy U.S. net product revenue in third quarter of 2025 Continued U.S. product growth driven by direct-to-consumer (DTC) investments and real-world... ► Artikel lesen | |
| LENZ THERAPEUTICS | 26,510 | 0,00 % | LENZ Therapeutics, Inc.: LENZ Therapeutics Announces Commercial Product Availability of VIZZ in the United States | VIZZ sample distribution initiated nationwide to Eye Care Professionals Commercial product shipments to be initiated in October to consumers with broad product availability by mid-Q4 2025 VIZZ is... ► Artikel lesen | |
| UPSTREAM BIO | 23,340 | -1,64 % | Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress | - Positive top-line results from VIBRANT Phase 2 trial of verekitug in CRSwNP reported in September showed statistically significant and clinically meaningful effects on primary and key secondary... ► Artikel lesen | |
| ARCELLX | 87,28 | -3,18 % | J&J, Legend withdraw ASH abstract assessing Carvykti against Gilead, Arcellx's rival CAR-T |
Das Unternehmen XSPRAY PHARMA AB kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,025 (+1,10 %) liegt der Kurs bei 2,290 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XSPRAY PHARMA AB finden Sie auf Wallstreet Online.